IN2012DN02368A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02368A
IN2012DN02368A IN2368DEN2012A IN2012DN02368A IN 2012DN02368 A IN2012DN02368 A IN 2012DN02368A IN 2368DEN2012 A IN2368DEN2012 A IN 2368DEN2012A IN 2012DN02368 A IN2012DN02368 A IN 2012DN02368A
Authority
IN
India
Prior art keywords
langerin
present
peptides
isolated anti
antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Jacques F Banchereau
Sandra Zurawski
Gerard Zurawski
Eynav Klechevsky
Sangkon Oh
Original Assignee
Baylor Res Insitute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Insitute filed Critical Baylor Res Insitute
Publication of IN2012DN02368A publication Critical patent/IN2012DN02368A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
IN2368DEN2012 2009-09-14 2010-09-14 IN2012DN02368A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24228309P 2009-09-14 2009-09-14
PCT/US2010/048800 WO2011032161A2 (en) 2009-09-14 2010-09-14 Vaccines directed to langerhans cells

Publications (1)

Publication Number Publication Date
IN2012DN02368A true IN2012DN02368A (enrdf_load_stackoverflow) 2015-08-21

Family

ID=43733140

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2368DEN2012 IN2012DN02368A (enrdf_load_stackoverflow) 2009-09-14 2010-09-14

Country Status (12)

Country Link
US (2) US20110081343A1 (enrdf_load_stackoverflow)
EP (1) EP2477655A4 (enrdf_load_stackoverflow)
JP (2) JP2013504599A (enrdf_load_stackoverflow)
CN (1) CN102711824A (enrdf_load_stackoverflow)
AR (1) AR078423A1 (enrdf_load_stackoverflow)
AU (1) AU2010291939B2 (enrdf_load_stackoverflow)
BR (1) BR112012005713A2 (enrdf_load_stackoverflow)
CA (1) CA2774140A1 (enrdf_load_stackoverflow)
IN (1) IN2012DN02368A (enrdf_load_stackoverflow)
MX (1) MX2012003058A (enrdf_load_stackoverflow)
TW (1) TWI483734B (enrdf_load_stackoverflow)
WO (1) WO2011032161A2 (enrdf_load_stackoverflow)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562104B2 (en) 2009-03-10 2017-02-07 Baylor Research Institute Anti-CD40 antibodies
EP2406290B1 (en) 2009-03-10 2017-07-05 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
ES2911752T3 (es) 2009-03-10 2022-05-20 Baylor Res Institute Anticuerpos contra CD40
TWI483734B (zh) 2009-09-14 2015-05-11 Baylor Res Inst 針對蘭格漢氏細胞（ｌａｎｇｅｒｈａｎｓ ｃｅｌｌｓ）之疫苗
MX2012012833A (es) 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
US20120301465A1 (en) * 2011-03-25 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods to immunize against hepatitis c virus
AR088428A1 (es) * 2011-08-25 2014-06-11 Baylor Res Inst Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CA2928908C (en) * 2013-11-01 2021-01-12 Pfizer Inc. Vectors for expression of prostate-associated antigens
EP3992210A1 (en) 2014-01-13 2022-05-04 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
EP3282014B1 (en) * 2015-02-12 2023-09-06 Tohoku University Cancer cell-specific anti-podocalyxin antibody and method for producing same
WO2017120280A1 (en) * 2016-01-06 2017-07-13 Virginia Tech Intellectual Properties, Inc. Antigen targeting to porcine langerin
EP3436059B1 (en) 2016-04-01 2022-01-12 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
US11162945B2 (en) * 2016-04-11 2021-11-02 Board Of Regents, The University Of Texas System Methods and compositions for detecting single T cell receptor affinity and sequence
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
BR112020014610A8 (pt) * 2018-01-18 2021-04-06 Humboldt Univ Zu Berlin uso de um veículo para direcionamento molecular, uso de uma composição, métodos para a entrega de carga direcionada e para identificar uma dose apropriada, composição farmacêutica, composição para diagnóstico, kit médico e vacina
WO2021239838A2 (en) 2020-05-26 2021-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CN111850004B (zh) * 2020-07-27 2022-04-22 齐鲁工业大学 一种活性提高的纤维小体对接蛋白突变体36740及应用
JP2023554587A (ja) 2020-11-12 2023-12-28 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｓａｒｓ－ｃｏｖ－２ スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用
EP4267176A1 (en) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
KR20230135620A (ko) 2021-01-29 2023-09-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 클라미디아 트라코마티스 항원 폴리펩타이드 및 백신목적을 위한 이의 용도
TWI815572B (zh) * 2021-09-27 2023-09-11 美商圖策智能科技有限公司 特定病毒的突變耐受表位的推估方法及系統
CA3238660A1 (en) 2021-11-17 2023-05-25 Institut National De La Sante Et De La Recherche Medicale Universal sarbecovirus vaccines
CN117343178A (zh) * 2022-07-04 2024-01-05 王昭 一种结合人cd207的抗体、抗人cd207的嵌合抗原受体及其应用
CN119948059A (zh) 2022-10-05 2025-05-06 法国国家健康医学研究院 靶向dc的抗尼帕病毒感染疫苗
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof
WO2025202674A1 (en) 2024-03-27 2025-10-02 Institut National de la Santé et de la Recherche Médicale Langerhans cells targeting hiv-1 vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685930B1 (en) * 1991-03-27 2004-02-03 Tanox, Inc. Methods and substances for recruiting therapeutic agents to solid tumors
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP5007409B2 (ja) 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション 樹状細胞に対するヒトモノクローナル抗体
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
AU2001258567A1 (en) 2000-05-19 2001-11-26 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
ES2337454T3 (es) * 2001-11-30 2010-04-26 The Government Of The Usa, As Represented By The Secretary Department Of Health And Human Services Peptidos agonistas de antigenos especificos de la protasa, y usos de los mismos.
US20060257412A1 (en) * 2003-03-04 2006-11-16 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP2481422A3 (en) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
CA2602434C (en) * 2005-04-08 2016-06-07 Argos Therapeutics, Inc. Dendritic cell compositions and methods
NZ592859A (en) * 2007-02-02 2012-05-25 Baylor Res Inst Multivariable antigens complexed with targeting humanized monoclonal antibody
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
US9109011B2 (en) * 2008-07-16 2015-08-18 Baylor Research Institute Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
EP2406290B1 (en) * 2009-03-10 2017-07-05 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
TWI483734B (zh) 2009-09-14 2015-05-11 Baylor Res Inst 針對蘭格漢氏細胞（ｌａｎｇｅｒｈａｎｓ ｃｅｌｌｓ）之疫苗

Also Published As

Publication number Publication date
US20140030264A1 (en) 2014-01-30
EP2477655A4 (en) 2014-02-12
US9315580B2 (en) 2016-04-19
CN102711824A (zh) 2012-10-03
CA2774140A1 (en) 2011-03-17
US20110081343A1 (en) 2011-04-07
WO2011032161A2 (en) 2011-03-17
EP2477655A2 (en) 2012-07-25
AU2010291939A1 (en) 2012-04-05
TWI483734B (zh) 2015-05-11
TW201116295A (en) 2011-05-16
BR112012005713A2 (pt) 2019-09-24
JP2013504599A (ja) 2013-02-07
WO2011032161A3 (en) 2011-08-25
AR078423A1 (es) 2011-11-09
JP2015110582A (ja) 2015-06-18
AU2010291939B2 (en) 2012-11-15
WO2011032161A8 (en) 2011-07-07
MX2012003058A (es) 2012-05-22

Similar Documents

Publication Publication Date Title
IN2012DN02368A (enrdf_load_stackoverflow)
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
TN2014000120A1 (en) Cd27l antigen binding proteins
TN2015000247A1 (en) Bcma antigen binding proteins
TN2017000173A1 (en) Antibody drug conjugates
EA201100268A1 (ru) Вакцина
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
BR112016030183A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
MX2015005810A (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
WO2010002478A3 (en) Glycopeptide and uses thereof
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2014000531A (es) Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
WO2014131019A3 (en) Her-1, her-3 and igf-1r compositions and uses thereof
HK1218860A1 (zh) 卵巢癌疫苗及接种方法
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2009003300A (es) Vectores de rhinovirus recombinantes.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
HK1200724A1 (en) Chlamydia antigen compositions and uses thereof